Literature DB >> 19833601

Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations.

Laurence Brugières1, Gaëlle Pierron, Agnès Chompret, Brigitte Bressac-de Paillerets, Federico Di Rocco, Pascale Varlet, Alain Pierre-Kahn, Olivier Caron, Jacques Grill, Olivier Delattre.   

Abstract

METHODS AND
RESULTS: Germline SUFU mutations were identified in two families with several children under 3 years of age diagnosed with medulloblastoma. All medulloblastomas in which the histology was reviewed were of the desmoplastic subtype, including three with the rare extensive nodularity subtype. In both families, the mutation detected in the SUFU gene was a frameshift mutation. Among the 25 mutation carriers identified in the two families, seven developed medulloblastomas.
CONCLUSIONS: This report highlights three features of SUFU related tumours. These are mainly medulloblastomas with extensive nodularity or typical desmoplastic/nodular medulloblastomas. These tumours mostly, if not exclusively, appear during the first 3 years of life. The penetrance of the mutation is incomplete.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833601     DOI: 10.1136/jmg.2009.067751

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  26 in total

1.  Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma.

Authors:  Ingrid Slade; Anne Murray; Sandra Hanks; Ajith Kumar; Lisa Walker; Darren Hargrave; Jenny Douglas; Charles Stiller; Louise Izatt; Nazneen Rahman
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

Authors:  Léa Guerrini-Rousseau; Christelle Dufour; Pascale Varlet; Julien Masliah-Planchon; Franck Bourdeaut; Marine Guillaud-Bataille; Rachid Abbas; Anne-Isabelle Bertozzi; Fanny Fouyssac; Sophie Huybrechts; Stéphanie Puget; Brigitte Bressac-De Paillerets; Olivier Caron; Nicolas Sevenet; Marina Dimaria; Sophie Villebasse; Olivier Delattre; Dominique Valteau-Couanet; Jacques Grill; Laurence Brugières
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 3.  Development and cancer of the cerebellum.

Authors:  Mary E Hatten; Martine F Roussel
Journal:  Trends Neurosci       Date:  2011-03       Impact factor: 13.837

Review 4.  Development of anticancer agents targeting the Hedgehog signaling.

Authors:  Xiangqian Zhang; Ye Tian; Yanling Yang; Jijun Hao
Journal:  Cell Mol Life Sci       Date:  2017-03-17       Impact factor: 9.261

5.  Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome.

Authors:  Katsunori Fujii; Hirofumi Ohashi; Maiko Suzuki; Hiromi Hatsuse; Tadashi Shiohama; Hideki Uchikawa; Toshiyuki Miyashita
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

6.  Members of the Rusc protein family interact with Sufu and inhibit vertebrate Hedgehog signaling.

Authors:  Zhigang Jin; Tyler Schwend; Jia Fu; Zehua Bao; Jing Liang; Huimin Zhao; Wenyan Mei; Jing Yang
Journal:  Development       Date:  2016-09-15       Impact factor: 6.868

Review 7.  Cerebellum development and medulloblastoma.

Authors:  Martine F Roussel; Mary E Hatten
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

Review 8.  Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway.

Authors:  Dengliang Huang; Yiting Wang; Jiabin Tang; Shiwen Luo
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 9.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

10.  Multiple skin hamartomata: a possible novel clinical presentation of SUFU neoplasia syndrome.

Authors:  Kirsty Mann; Jill Magee; Marine Guillaud-Bataille; Christophe Blondel; Brigitte Bressac-de Paillerets; Josie Yeatman; Ingrid Winship
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.